BACKGROUND: The correlation between treatment-related factors and lung toxicity has not been sufficiently evaluated in salvage radiotherapy. METHODS: Twenty-one patients with recurrent non-small-cell lung cancer (NSCLC) after lobectomy received salvage radiotherapy to a total dose of 46-60 Gy. The effects of radiotherapy parameters on the development of radiation pneumonitis (RP) were examined using dose-volume histograms. RESULTS: Grade 1 RP was observed in 4, grade 2 in 2, and grade 3 in 1 patient. Patients who developed RP had a significantly higher value in V dose (V13, V20) parameters and mean lung dose (MLD) than those who did not develop RP. Concerning G2 or higher RP, 3 patients who developed > or = G2 RP had a significantly higher value in V20, V13, and MLD than the remaining patients with P values of 0.01, 0.015, and 0.016, respectively. The mean V20, V13, and MLD in these 3 patients were 27%, 29.3%, and 14.8 Gy, respectively, whereas the mean V20, V13, and MLD in the remaining 18 patients were 15.8%, 18.3%, and 8.8 Gy, respectively. Three of 6 patients with a V20 > or = 20% developed > or = G2 RP whereas this did not occur in the remaining patients (P = 0.015). Similarly, 3 of 6 patients with a V13 > or = 23% developed > or = G2 RP whereas this did not occur in the remaining patients (P = 0.015). CONCLUSIONS: These data suggest that a somewhat lower V dose value or MLD, as compared with the setting of definitive radiotherapy, could be a surrogate for RP in patients undergoing salvage radiotherapy for recurrent NSCLC.
BACKGROUND: The correlation between treatment-related factors and lung toxicity has not been sufficiently evaluated in salvage radiotherapy. METHODS: Twenty-one patients with recurrent non-small-cell lung cancer (NSCLC) after lobectomy received salvage radiotherapy to a total dose of 46-60 Gy. The effects of radiotherapy parameters on the development of radiation pneumonitis (RP) were examined using dose-volume histograms. RESULTS: Grade 1 RP was observed in 4, grade 2 in 2, and grade 3 in 1 patient. Patients who developed RP had a significantly higher value in V dose (V13, V20) parameters and mean lung dose (MLD) than those who did not develop RP. Concerning G2 or higher RP, 3 patients who developed > or = G2 RP had a significantly higher value in V20, V13, and MLD than the remaining patients with P values of 0.01, 0.015, and 0.016, respectively. The mean V20, V13, and MLD in these 3 patients were 27%, 29.3%, and 14.8 Gy, respectively, whereas the mean V20, V13, and MLD in the remaining 18 patients were 15.8%, 18.3%, and 8.8 Gy, respectively. Three of 6 patients with a V20 > or = 20% developed > or = G2 RP whereas this did not occur in the remaining patients (P = 0.015). Similarly, 3 of 6 patients with a V13 > or = 23% developed > or = G2 RP whereas this did not occur in the remaining patients (P = 0.015). CONCLUSIONS: These data suggest that a somewhat lower V dose value or MLD, as compared with the setting of definitive radiotherapy, could be a surrogate for RP in patients undergoing salvage radiotherapy for recurrent NSCLC.
Authors: Artyom Sedrakyan; Jan Van Der Meulen; Ken O'Byrne; Joseph Prendiville; Jennifer Hill; Tom Treasure Journal: J Thorac Cardiovasc Surg Date: 2004-09 Impact factor: 5.209
Authors: M V Graham; J A Purdy; B Emami; W Harms; W Bosch; M A Lockett; C A Perez Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: Yvette Seppenwoolde; Joos V Lebesque; Katrien de Jaeger; José S A Belderbos; Liesbeth J Boersma; Cees Schilstra; George T Henning; James A Hayman; Mary K Martel; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-01 Impact factor: 7.038
Authors: Jinli Ma; Junan Zhang; Sumin Zhou; Jessica L Hubbs; Rodney J Foltz; Donna R Hollis; Kim L Light; Terence Z Wong; Christopher R Kelsey; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2008-12-10 Impact factor: 7.038
Authors: Weijie Xiong; Qingfeng Xu; Yong Xu; Changjin Sun; Na Li; Lin Zhou; Yongmei Liu; Xiaojuan Zhou; Yongsheng Wang; Jin Wang; Sen Bai; You Lu; Youling Gong Journal: BMC Cancer Date: 2014-09-26 Impact factor: 4.430
Authors: L Nicosia; L Agolli; C Reverberi; V De Sanctis; L Marinelli; G Minniti; J Di Muzio; M Valeriani; M F Osti Journal: Radiat Oncol Date: 2018-10-23 Impact factor: 3.481